Skip to Main content Skip to Navigation
Journal articles

Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin–angiotensin–aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study

Abstract : Numerous studies demonstrate parallels between CVD, type 2 diabetes mellitus (T2DM) and COVID-19 pathology, which accentuate pre-existing complications in patients infected with COVID-19 and potentially exacerbate the infection course. Antidiabetic drugs such as sodium-glucose transporter-2 (SGLT-2) inhibitors have garnered substantial attention recently due to their efficacy in reducing the severity of cardiorenal disease. The effect of SGLT-2 inhibitors in patients with COVID-19 remains unclear particularly since SGLT-2 inhibitors contribute to altering the RAAS cascade activity, which includes ACE-2, the major cell entry receptor for SARS-CoV2. A study, DARE-19, was carried out to unveil the effects of SGLT-2 inhibitor treatment on comorbid disease complications and concomitant COVID-19 outcomes and demonstrated no statistical significance. However, the need for further studies is essential to provide conclusive clinical findings.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03627229
Contributor : U1034 INSERM Connect in order to contact the contributor
Submitted on : Friday, April 1, 2022 - 10:45:14 AM
Last modification on : Wednesday, April 6, 2022 - 3:32:24 AM
Long-term archiving on: : Saturday, July 2, 2022 - 6:28:10 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Diala Alhaj Moustafa, Zainab Imran, Roua Ismail, Menatallah Rayan, Alain-Pierre Gadeau, et al.. Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin–angiotensin–aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study. Molecular Biology Reports, Springer Verlag, 2022, 49 (3), pp.2321-2324. ⟨10.1007/s11033-022-07183-w⟩. ⟨inserm-03627229⟩

Share

Metrics

Record views

9